International Clinical Trial: RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808138) titled 'RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The Netherlands Cancer Institute

Condition: Non Small Cell Lung Cancer Immunotherapy

Intervention: Drug: Cemiplimab 350 mg IV

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: November 2026

Target Sample Size: 30

Countries of Recruitment: Netherlands

To know more, vi...